Key Highlights
- CAPRISA is a leading research center in HIV and TB prevention, recognized globally for its contributions to understanding disease pathogenesis and treatment.
- The organization collaborates with top institutions and global leaders to stay at the forefront of scientific research and trends.
- CAPRISA offers a dynamic and innovative environment for professionals seeking to advance their careers in HIV and TB research.
- The research conducted by CAPRISA has significant implications for public health policies and treatment strategies worldwide.
- CAPRISA's work is crucial in bridging the gap between scientific research and practical applications in healthcare.
About CAPRISA
CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research, established in 2002. It conducts globally relevant and locally responsive research to understand HIV pathogenesis, prevention, and epidemiology, as well as the links between tuberculosis and AIDS care. CAPRISA collaborates with global leaders in HIV and TB research to stay updated on the latest scientific trends. The organization operates through four main scientific programs: HIV Pathogenesis and Vaccines, HIV and TB treatment, Microbicides, and Prevention and Epidemiology.
Founded by five partner institutions, CAPRISA provides a unique opportunity for professionals to engage in cutting-edge research in HIV and TB prevention and treatment. The organization offers a dynamic environment for career growth and professional development. For the latest news and employment opportunities, visit the CAPRISA website or follow them on social media.
CAPRISA's research focuses on developing innovative strategies to combat HIV and TB, contributing to global health advancements. The organization's commitment to scientific excellence and community impact makes it a key player in the fight against these diseases.
Leadership Team
Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.
Company Facts
| Ownership Private Company |
Why Contact CAPRISA?
B2B professionals can partner with CAPRISA to leverage its cutting-edge research in HIV and TB prevention and treatment. Collaborating with CAPRISA offers access to a network of global leaders and the latest scientific trends, enhancing the impact of your products and services in the healthcare sector.
Who Should Contact CAPRISA for Business?
Sales teams selling healthcare products, recruiters seeking roles in medical research, and partners offering services related to HIV and TB prevention should reach out to CAPRISA.
Categories
- HIV Research
- TB Prevention
- Medical Research
- Public Health
- Scientific Collaboration
- Global Health
- Pathogenesis
- Vaccines
- Microbicides
- Epidemiology
More Medical Research Companies
Frequently Asked Questions
- What does CAPRISA do?
- CAPRISA is a globally recognised HIV and TB research centre that conducts clinical trials and research in fields such as epidemiology, virology, immunology, and infectious disease medicine.
- How many employees does CAPRISA have?
- CAPRISA has approximately 426 employees.
- Where is CAPRISA headquartered?
- The headquarters of CAPRISA is located in Durban, South Africa.
- What industry is CAPRISA in?
- CAPRISA operates in Medical Research, Public Health, HIV/TB Prevention.
- When was CAPRISA founded?
- CAPRISA was founded in 2002.
- What is the email format at CAPRISA?
- CAPRISA uses the email format first.last@caprisa.org.
- Is CAPRISA still active?
- Yes, CAPRISA was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
- How do I sell to CAPRISA?
- Research CAPRISA's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.
Ready to Sell to CAPRISA?
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Backed by startup programs from
Connect with CAPRISA